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Mitochondria play a key role in signal transduction, redox homeostasis and cell survival, 
which extends far beyond their classical functioning in ATP production and energy 
metabolism. In living cells, mitochondrial content (“mitochondrial mass”) depends on the 
cell-controlled balance between mitochondrial biogenesis and degradation. These processes 
are intricately linked to changes in net mitochondrial morphology and spatiotemporal 
positioning (“mitochondrial dynamics”), which are governed by mitochondrial fusion, fission 
and motility. It is becoming increasingly clear that mitochondrial mass and dynamics, as well 
as its ultrastructure and volume, are mechanistically linked to mitochondrial function and the 
cell. This means that proper quantification of mitochondrial morphology and content is of 
prime importance in understanding mitochondrial and cellular physiology in health and 
disease. This review first presents how cellular mitochondrial content is regulated at the level 
of mitochondrial biogenesis, degradation and dynamics. Next we discuss how mitochondrial 
dynamics and content can be analyzed with a special emphasis on quantitative live-cell 








Mitochondria house enzyme systems for -oxidation of fatty acids, the tricarboxylic acid 
(TCA) cycle, ketogenesis and oxidative phosphorylation (OXPHOS) and as such are key 
generators of cellular energy in the form of ATP [1-3]. In addition, this organelle plays an 
important role in the physiology of mammalian cells through its involvement in reactive 
oxygen species (ROS) generation, calcium homeostasis, heat generation and apoptosis 
induction (see [4, 5] and the references therein). Structurally, mitochondria consist of an outer 
membrane (MOM) that surrounds the inner membrane (MIM). The MIM is highly folded 
(“cristae”) and encloses the matrix compartment where metabolic enzymes and the 
mitochondrial DNA (mtDNA) reside [6-9]. ATP is produced via the combined action of the 
four MIM-embedded complexes (CI-CIV) of the electron transport chain (ETC) and by the 
MIM-embedded complex V (CV or the FoF1-ATPase) through a chemiosmotic coupling 
mechanism [3, 9, 10]. Together, CI-CV constitute the oxidative phosphorylation (OXPHOS) 
system, the proper functioning of which critically depends on the functional and structural 
integrity of MIM protein and lipid components. Given their role in numerous cellular 
pathways, it is not surprising that dysfunction of mitochondria is observed in many human 
pathologies. In principle, there are only two categories of mitochondrial diseases [4]: primary 
disorders (in which one of the 1200-1500 genes encoding a mitochondrial protein is mutated) 
and secondary disorders (where mitochondria are dysfunctional for a different reason). In this 
sense, (progressive) mitochondrial dysfunction has not only been linked to (relatively rare) 
metabolic disorders but also to normal human aging, neurodegeneration, cancer, diabetes and 
metabolic syndrome (e.g. [4, 5, 11-16]). Although mitochondria display a certain genetic and 
metabolic autonomy, their function is intricately linked to cellular physiology at the level of 
ion/metabolite exchange and (retrograde) signaling cascades [10, 17]. In addition, the cellular 
environment normally supplies mitochondria with (submaximal) substrate concentrations and 
sustains and controls mitochondrial (ultra)structure and motility (“mitochondrial dynamics). 
We and others therefore argued that mitochondrial (patho)physiology, if possible, should be 
studied in living cells, tissues and organisms (see [4, 5] and the references therein). During the 
last decade it has become increasingly clear that mitochondrial (dys)functioning, amount, 
(ultra)structure and subcellular positioning are tightly interconnected (e.g. [18-23]). 
Furthermore, the functional roles of mitochondria in metabolism and signaling appear to 
depend on the physical compartmentalization, subcellular localization and motility of the 
organelles, and vice versa. Clearly, changes in mitochondrial motility, fission and fusion 
Page 4 of 37 
 
dynamics coincide with phenomena such as bioenergetic adaptation, cellular stress, autophagy 
and cell death, as well as pathological mechanisms involving mitochondrial dysfunction [24]. 
Moreover, mitochondrial morphology and mass can be modulated by various pharmacological 
treatments (Table 1). This has made the topics of mitochondrial dynamics, cellular 
mitochondrial content and its regulation subjects of intense study. Below, we summarize the 
current insights into how mitochondrial content is regulated (section 2) and discuss 
experimental strategies to quantify mitochondrial content (section 3).  
 
2. REGULATION OF MITOCHONDRIAL CONTENT  
One of the main purposes of mitochondria is to provide energy-consuming processes with an 
adequate supply of ATP. However, under certain conditions, cellular energy demands may 
exceed the mitochondrial capacity of ATP production, causing mild or severe energy 
depletion (“energy crisis”). This may either be the result of increased energy expenditure such 
as with endurance training, or due to a functional mitochondrial defect or mutation, relevant 
during pathological conditions. During energy crisis, ATP deficiency and/or mitochondrial 
dysfunction will activate adaptive mechanisms attempting to counterbalance this situation [23, 
24, 42-44]. These interlinked regulatory systems control mitochondrial content at the 
transcriptional and functional level by modulating mitochondrial biogenesis/degradation, 
fission/fusion dynamics, motility and/or respiration [23]. Of note, mitochondrial content 
modulation might not work identically in the various cell types because of their different 
biological function and mitochondrial morphology (Fig. 1). This is compatible with the 
observation that mitochondrial abundance and expression levels of OXPHOS complexes 
apparently correlate with tissue- and cell-specific requirements of oxidative ATP generation 
[45, 46]. Below, we briefly discuss the three levels of regulation affecting mitochondrial 
content in more detail (Fig. 2): (i) regulation of mitochondrial biogenesis, (ii) regulation of 
mitochondrial degradation, (iii) regulation of mitochondrial dynamics.  
 
2.1. MITOCHONDRIAL BIOGENESIS 
Mitochondrial biogenesis can be defined as division and/or “growth” (e.g. elongation by 
fusion) of pre-existing mitochondria, serving to increase or replenish mitochondrial biomass 
[47]. Under physiological conditions, this process is an important adaptive mechanism to 
accommodate metabolic changes or energy depletion since it increases mitochondrial mass 
and, as a consequence, mitochondrial bioenergetic capacity. Biogenesis is observed after 
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endurance exercise, cold exposure and caloric restriction but also during conditions of 
oxidative stress and throughout cell division and differentiation [42, 46, 48-51]. Furthermore, 
thyroid hormones are known to increase metabolic rate and mitochondrial enzyme levels in 
rats [52], and both pre- and postnatal changes in mitochondrial biogenesis have been 
documented [53-55]. For instance, during embryonic development energy metabolism and 
mitochondrial (ultra)structure are remodeled in parallel [56]. At the early stage of 
embryogenesis (embryonic day 1), the zygotes contain spheroid mitochondria and depend on 
OXPHOS after which anaerobic glycolysis gradually takes over and reaches a maximum level 
following implantation. After this, glycolytic ATP generation becomes progressively less 
important because mitochondrial biogenesis is triggered and OXPHOS is reinitiated due to 
vascularization. Mitochondrial biogenesis is generally considered as a long-term adaptive 
response and not a transient accommodation to short fluctuations in energy supply. The latter 
can be met by enhancing mitochondrial capacity via posttranscriptional regulation (e.g. 
phosphorylation, (de)acylation, oxidative modification) and/or expression regulation of only a 
subset of mitochondrial proteins (e.g. [57-59]). In case of genetic mitochondrial disorders, 
increased mitochondrial biogenesis in skeletal muscle can be diagnostically observed as 
“ragged red fibres” [60]. In humans, about 1000 genes encoding mitochondrial proteins have 
been identified (MitoCarta human inventory, Broad Institute). The majority of these genes is 
located on the nuclear DNA (nDNA) since only 13 of them (all encoding subunits of the 
OXPHOS system) originate from mtDNA. Nuclear-encoded mitochondrial proteins are 
guided to their correct location in the outer or inner membranes, the inter membrane space or 
the matrix (for details see [61] and the references therein). This means that mitochondrial 
biogenesis requires an intricate control network of transcriptional regulators to properly 
orchestrate the coordinated expression of mtDNA and nDNA-encoded mitochondrial proteins 
during mitochondrial biogenesis [58, 62]. This information exchange is triggered by 
mitochondrial (dys)function, including alterations in MIM membrane potential (), 
OXPHOS dysfunction and reduced mitochondrial and/or cytosolic ATP levels [63]. 
Controlling mitochondrial biogenesis not only involves nuclear-to-mitochondrial 
communication but also mitochondria-to-nucleus (“retrograde”) signaling [64]. Directly 
below, we discuss the key proteins involved in transcriptional regulation of mitochondrial 




PGC-1α - One of the major players in mitochondrial biogenesis is the transcriptional 
coactivatior peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) [65, 
66]. PGC-1α was first identified as a regulator of adaptive thermogenesis by regulating the 
expression of the mitochondrial uncoupling protein-1 (UCP-1) in brown fat [67]. Further 
research revealed that PGC-1α is highly expressed in mitochondria-rich tissues including 
heart and skeletal muscle [46, 68]. PGC-1α binds to, and regulates the activities of, several 
transcription factors and nuclear hormone receptors involved in mitochondrial biogenesis 
[65]. In this sense, PGC-1α coactivates nuclear respiratory factor-1 (NRF-1) [66], estrogen-
related receptor alpha (ERRα) [69] and myocyte enhancer factor 2 (MEF2) [70]. Thereby it 
controls expression of several ETC and other mitochondrial proteins. In addition, PGC-1α is 
involved in fatty acid metabolism because it regulates peroxisome proliferator-activated 
receptors (PPARs) (for details see [42, 65] and the references therein).   
 
NRF-1 - NRF-1 is a 68-kDa protein that is ubiquitously expressed in embryonic, fetal and 
adult tissues, with highest expression in skeletal muscle [47, 71]. It has a central DNA binding 
domain flanked by a nuclear localization signal and a transcriptional activation domain. NRF-
1 binds to the recognition site in the target gene promoter region, as a homodimer, and 
activates transcription of the gene [72, 73]. NRF-1 DNA binding and trans-activation function 
is enhanced by serine phosphorylation of its N-terminal domain [74, 75]. NRF-1 recognition 
sites are found in in the proximal promoter of ubiquitously expressed genes [76], many of 
which are involved in mitochondrial biogenesis and metabolism [77]. Expression of a 
substantial number of nDNA-encoded OXPHOS genes has been linked to NRF-1 activity 
[78]. Moreover, NRF-1 has been found to regulate expression of key components of the 
mitochondrial protein import machinery, cytochrome c, and the rate-limiting enzyme in heme 
biosynthesis, 5-aminolevuline [79-81]. NRF-1 also regulates transcription factor A, 
mitochondrial (TFAM) [72], involved in transcription regulation of mtDNA-encoded genes 
and mitochondrial genome replication [82]. TFAM is required for the expression of the 
mitochondrial RNA polymerase (POLRMT) and the transcription factor B (TFB) regulators 
[83], two components of the mitochondrial transcription complex. Transcription of 
mitochondrial ribosomal proteins and tRNA synthases are also regulated by NRF-1 [84]. 
Genetic and biochemical analysis revealed that interactions between PGC-1α, NRF-1 and 
TFAM (co)control mitochondrial biogenesis and respiratory capacity [78]. Mitochondrial 
biogenesis stimulated by PGC-1α requires functional NRF-1, since a dominant negative NRF-
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1 allele blocks the function of PGC-1 α [66]. The expression of both NRF-1 and PGC-1α has 
been found to be reduced in diabetes [85] and both factors have also been shown to be 
induced as a part of the adaptation of skeletal muscle to exercise training [86]. There are many 
other examples of mitochondrial content regulation via NRF-1 and associated mechanisms. 
For instance, NRF-1 and its downstream factor TFAM is upregulated in cells depleted of 
mtDNA and in rat hepatocytes following lipopolysaccharide treatment [87, 88]. In both of 
these model systems increased ROS levels were observed, suggesting that oxidative stress 
and/or redox changes might trigger mitochondrial biogenesis. It has also been suggested that 
NRF-1 might control the expression of ETC proteins in response to both extracellular signals 
and intracellular ATP concentrations [42]. With respect to the latter, another well described 
route of NRF-1-regulated mitochondrial biogenesis involves activation of AMP-dependent 
protein kinase (AMPK), a major sensor of cellular energy status [89-91]. AMPK is activated 
by AMP, which builds up during low energy (i.e. low ATP) conditions such as nutrient 
deprivation, physical exercise and/or bioenergetics dysfunction [92, 93]. AMPK activation in 
response to energy depletion stimulates expression of PGC-1α, triggering activation of NRF-
1-mediated gene transcription [66, 94]. Interestingly, AMPK activation by the 
pharmacological agent 5-aminoimidazole-4-carboxamide riboside (AICAR) has been found to 
induce NRF-1 transcriptional activity through PGC-1α co-activation in various studies (e.g. 
[32, 95, 96]). The latter might explain the positive effects of AICAR in animal models of 
mitochondrial disease and fibroblast from patients with mitochondrial dysfunction [97, 98]. 
Upregulation of both NRF-1 and TFAM in skeletal muscle has also been associated with 
aging, suggesting that mitochondrial biogenesis is induced to compensate for mitochondrial 
functional deterioration [99].  
 
NRF-2 - Another NRF family member, NRF-2, has also been found to regulate gene 
promoters of ETC subunits [100]. Occasionally, NRF-1 and NRF-2 recognition sites are 
present in the same promoter regions, suggesting that these factors act together in 
coordinating protein expression in relation to mitochondrial biogenesis (see [94] and the 
references therein).  
 
PPARs - The PPAR family of ligand-activated transcription factors comprises several 
isoforms including PPARα, PPARβ and PPARγ [101]. These variants display different tissue-
specific expression patterns and coordinate the expression of metabolic genes involved in 
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glucose and lipid metabolism [101, 102]. PPARs heterodimerize with the retinoid X receptor 
(RXR), and trans-activate target genes with compatible responsive elements in the promoter 
region encoding both mitochondrial and non-mitochondrial proteins. However, to the best of 
our knowledge, PPARs have not been directly associated with expression of ETC components 
[42]. PPARs are typically activated by long-chain fatty acids and their metabolites [103]. The 
PPARα isoform is expressed in cells with high rates of mitochondrial fatty acid oxidation, 
such as liver, heart, kidney and skeletal muscle, intestine and pancreas [101, 104]. The 
PPARβ isoform is ubiquitously expressed, and has been implicated in fatty acid oxidation as 
well as other mitochondrial processes [105, 106].  PPARγ is abundantly expressed in adipose 
tissue and at lower levels in skeletal muscle, liver, heart and bone marrow stromal cells, and 
regulates glucose metabolism and insulin sensitivity, and UCP-1-mediated thermogenesis 
[107].  
 
ERRs - ERR transcription factors are involved in gene regulatory control networks involved 
in energy homeostasis, including fat and glucose metabolism as well as mitochondrial 
biogenesis and function [42, 108, 109]. Similar to PPARs and NRFs, ERRs are also co-
activated by PGC-1α and expressed in tissues with high energy demands.  
 
2.2. MITOCHONDRIAL DEGRADATION 
Mitochondrial quality control occurs at the level of organelle and protein integrity and is 
carried out via mechanisms that identify the compromised components and marks them for 
destruction, followed by the subsequent recruitment of the machinery responsible for their 
degradation [11, 13, 110-113]. Quality control of mitochondrial proteins is described in detail 
elsewhere (e.g. [11, 114]). The specific degradation of dysfunctional mitochondria 
(“mitophagy”) is carried out by the lysosomal-autophagic machinery after the dysfunctional 
organelles have been marked for destruction. Key mediators of mitophagy include the PTEN 
(phosphatase and tensin homolog)-induced putative kinase 1 (PINK1), presenilin-associated 
rhomboid-like (PARL) protein and Parkin, a component of a multiprotein E3 ubiquitin ligase 
complex. PINK1 is normally located on the MOM, but is found at relatively low amount due 
to its continuous degradation by mitochondrial proteases [115-117]. Under conditions of (full) 
mitochondrial depolarization, this proteolytic activity is (fully) blocked leading to PINK1 
accumulation on the MOM. When present at this location, PINK1 recruits cytoplasmic Parkin. 
This process therefore serves as a quality control mechanism for detecting and tagging 
Page 9 of 37 
 
dysfunctional mitochondria, with low membrane potential, for degradation by 
mitophagy/autophagy. Interestingly, evidence was provided that Parkin also regulates the 
mitochondrial fission/fusion balance (see below) by ubiquitylation of fusion-promoting 
proteins (Mitofusins) on the MOM [118]. Mitochondrial fission is required to segregate 
dysfunctional mitochondria from the functional mitochondrial population and allow 
mitophagy. The current mechanism proposes that dysfunctional mitochondria have a 
(partially?) depolarized  and, as a consequence, are trapped in autophagosomes for further 
lysosomal degradation. Mutations in the genes encoding PINK1 or Parkin have been 
implicated in early onset autosomal recessive Parkinson’s disease, suggesting that 
mitochondrial quality control is of significance in this neurodegenerative pathology [119, 
120]. Another protein involved in Parkinson’s disease, α-synuclein, also appears to play a role 
in mitochondrial quality control. However, the nature of this involvement is currently not 
fully understood [121-123]. Obviously, mitochondrial biogenesis and degradation by 
mitophagy act antagonistically, but at the same time complementary; and together they 
determine net mitochondrial content and mitochondrial quality. However, experimental 
evidence suggests that mitochondrial biogenesis and autophagy are also more directly 
connected via the Parkin Interacting Substrate (PARIS) protein [124]. PARIS appears to be a 
repressor of PGC-1α by inhibiting its expression thereby inhibiting mitochondrial biogenesis. 
On the other hand, being a Parkin substrate, PARIS is degraded by the proteasome upon 
Parkin activation. A mechanism was proposed in which reduced Parkin expression/activity, as 
observed in Parkin-associated Parkinson’s disease, leads to increased PARIS levels thereby 
affecting the balance between mitochondrial biogenesis and mitophagy [124]. Such a 
mechanism might amplify the negative effect of Parkin mutations on mitochondrial quality 
control [116]. In addition to the Pink1/Parkin system, several other proteins (e.g. valosin-
containing protein (VCP), the p62 protein, microtubule-associated protein 1 light chain (LC3), 
the Bcl2/adenovirus E1B 19-kDa protein-interacting protein 3 (Bnip3), the mitochondrial 
voltage-dependent anion channel (VDAC) and the Nix protein) have been implicated in 
mitophagy induction, regulation and execution but these are discussed elsewhere [125-128]. 
 
2.3. MITOCHONDRIAL DYNAMICS 
Mitochondrial morphology varies between different cell types, ranging from bean-shaped 
individual organelles to reticular structures (Fig.1). For example, in healthy rat hepatocytes 
mitochondria are evenly distributed throughout the cell and their structure is generally 
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spherical/ovoid (e.g. [129]). Mitochondrial reticular assemblies generally extend throughout 
the cytosol and are often closely juxtaposed to other cellular compartments like the nucleus 
and endoplasmic reticulum [130-132]. Mitochondrial morphology is, however, very dynamic 
and can shift between fragmented structures and tubular networks, via altering the balance 
between mitochondrial movement, fission and fusion events [133]. This balance determines 
the net morphology of the cellular mitochondrial population and is controlled by the activities 
of a growing set of “mitochondria-shaping” proteins (Fig.2; [134-143]). In mammals key 
proteins include mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2), involved in MOM fusion; OPA1 
(optic atrophy protein 1; MIM fusion), dynamin-related protein 1 (Drp1; MOM fission), and 
Fission protein 1 (Fis1; a Drp1-adaptor protein); and Miro and Milton (both involved in 
mitochondrial motility). At the posttranslational level, the activities of mitochondrial 
fusion/fission proteins is regulated by an collection of regulatory components (Fig. 2; details 
provided in [20, 143-148]). Interestingly, mitochondrial fusion and fission proteins also are 
directly involved in regulation of mitochondrial functional properties, strongly suggesting that 
mitochondrial shape, spatiotemporal localization and function are linked [135, 140, 149-155]. 
For instance, fragmentation and fusion events, and therefore also membrane remodeling, 
occurs both in response to metabolic influence and as part of cell death programs [135, 156, 
157]. Moreover, Mfn2 loss-of-function inhibited pyruvate, glucose and fatty acid oxidation 
and induced mitochondrial depolarization [158]. In contrast, Mfn2 gain-of-function increased 
glucose oxidation and mitochondrial membrane potential. This suggests that Mfn2 
(co)regulates mitochondrial function through a mechanism independent of its role in 
mitochondrial fusion. The mitochondrial volume fraction in the cell depends on the cell type 
and metabolic condition [159, 160]. In this sense, multiple mitochondrial abnormalities may 
be observed in muscle and skin cells of patients with inherited mitochondrial disorders (e.g. 
[161, 162]). Similarly, when mitochondrial function was chronically inhibited by rotenone, a 
specific blocker of the first ETC complex (CI), mitochondrial length and degree of branching 
dose-dependently increased [37, 163]. In the light of the above, and given the fact that 
mitochondrial shape and mass also can differ within and between the same cell type (e.g. 
[149, 150, 162]), a proper understanding of the relationship between mitochondrial content, 
shape and function requires statistical analysis. For this purpose functional and microscopy-
based strategies have been developed, which are discussed in the following sections.  
 
3. QUANTIFICATION OF MITOCHONDRIAL MORPHOLOGY AND CONTENT 
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Methods to evaluate mitochondrial function have been a topic of major interest in 
experimental research, pharmacological screening and clinical diagnostics. There are multiple 
experimental approaches to measure individual or composite mitochondrial properties. 
Common analyses include biochemical measurements of mitochondrial marker proteins and 
enzyme activities, quantitation of mtDNA level and fluorescence microscopy analysis [40, 45, 
164, 165]. Also (cryo)-electron microscopy (EM) analysis of fixed specimens has been widely 
applied to analyze mitochondrial (ultra)structure (e.g. [41, 166-168]). As a consequence, 
morphometric analyses have been historically important to quantify mitochondrial properties 
using EM images [169]. New developments in the EM field, including tomography and image 
processing tools, have extended the analytic potential by enabling 3D-reconstruction, 
detection and segmentation of mitochondria, which has proven to be powerful methods to 
study mitochondrial internal and external structure. Additional information regarding EM 
analysis of mitochondrial (ultra)structure can be found elsewhere [170-180]. Below we 
discuss three other methodological approaches to assess mitochondrial morphology and/or 
content in biological samples: (i) bioenergetic capacity, (ii) biochemical biomarkers, and (iii) 
fluorescence microscopy analysis.  
 
3.1. MITOCHONDRIAL BIOENERGETIC CAPACITY 
Quantification of oxygen consumption rates is frequently used to assess mitochondrial 
oxidative capacity and thereby mitochondrial content in isolated mitochondria and 
(permeabilized) cells and tissue samples (e.g. [38-40, 181-185]). The strategy of isolating 
mitochondria from human and animal tissue/cell material has historically been very 
important, and the technique was pioneered by scientists such as Chance and Williams [186]. 
Analysis of mitochondria-enriched fractions led to the formulation of Mitchell’s 
chemiosmotic theory [3] and the subsequent elucidation of other mitochondrial metabolic 
pathways like the TCA cycle [187]. Currently, optimized protocols for mitochondrial isolation 
from a variety of tissues and cells are available (e.g. [188, 189]). However, isolated 
mitochondria are relatively fragile and their morphology and function differs with that 
observed in living cells [190]. The latter relates to the fact that in situ mitochondrial function 
is closely linked to cell metabolism and associated with submaximal rates of mitochondrial 
enzyme activity. Moreover, as explained above, the cellular environment mediates 
communication between mitochondria the cytosol and other organelles during forward and 
retrograde mitochondrial signaling [154]. This means that data obtained with mitochondria-
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enriched fractions is not necessarily informative about mitochondrial (patho)physiology at the 
cellular and tissue level. To overcome some of the adverse effects caused by the isolation 
procedure, permeabilization of the cellular membrane has been used as an alternative 
procedure to access mitochondrial activities. Using this method, mitochondrial function can 
be studied without dislocating the organelles from the intracellular compartment, and the 
metabolic conditions and substrate concentrations can still be controlled [181, 191]. However, 
the nature and significance of mitochondrial changes taking place during subcellular isolation 
is still under debate [192].    
 
3.2. BIOCHEMICAL BIOMARKERS 
Another common method to determine mitochondrial content involves analysis of the protein 
levels of (a collection of) mitochondrial proteins such as OXPHOS subunits and/or membrane 
transporters in cell or tissue lysates (e.g. [25, 40]). Similarly, analysis of individual enzyme 
activities under non-substrate limiting (Vmax) conditions generally reflects the levels of 
mitochondrial OXPHOS proteins (e.g. [193]). Indeed, analysis of cells from patients with 
isolated CI deficiency, maximal CI enzymatic activity and the amount of fully-assembled CI 
(determined by native gel electrophoresis) proportionally declined [194]. However, 
mitochondrial content was not reduced in these cells [150], demonstrating that OXPHOS 
protein levels and Vmax values not always reflect mitochondrial content. An alternative 
strategy to analyze mitochondrial biogenesis and content involves quantification of mRNA 
levels of nDNA-encoded genes of OXPHOS subunits and mitochondrial transcription 
regulators (e.g. [40, 183]). Furthermore, recent progress in real-time quantitative PCR 
technology has enabled sensitive analysis of mtDNA copy number in small sample volumes 
[195]. By this method mtDNA content is quantified relative to nDNA, yielding a 
mitochondrial-to-nuclear DNA ratio as measure of mtDNA copy number, which was used as 
a measure of mitochondrial content in animal and clinical studies [40, 196-198]. It should, 
however, be mentioned that changes in OXPHOS protein expression or mtDNA levels do not 
always correlate with changes in mitochondrial content (e.g. [199, 200]). The expression level 
and/or the activity of citrate synthase, a mitochondrial matrix enzyme, is commonly used as a 
reference when evaluating relative changes in mitochondrial properties or as a surrogate 
marker of total mitochondrial volume and content (e.g. [193]). The protein amount of several 
marker enzymes can also be evaluated using histochemical staining of tissue preparations, 
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including nicotinamide adenine dinucleotide tetrazolium reductase [201], cytochrome c 
oxidase [202] and succinate dehydrogenase [203, 204]. 
 
3.3. FLUORESCENCE MICROSCOPY 
Microscopy techniques have been essential in mitochondrial research since the discovery of 
these organelles back in the 1840’s [205]. Nowadays, mitochondrial analysis by live-cell 
microscopy represents the most direct method to retrieve authentic information about 
mitochondrial shape, position and content. Development of superresolution microscopy 
techniques has allowed imaging of fluorescently labeled cells and organelles at unprecedented 
levels of resolution [206-212]. For example, using three-dimensional (3D) structured-
illumination microscopy (SIM) resolution was doubled relative to a wide-field fluorescence 
microscope yielding values of 120 nm (lateral) and 360 nm (axial). The SIM approach 
allowed live-cell recordings of mitochondrial (ultra)structure in living cells at up to 5 s per 
volume for >50 time points [213].  
 
Visualization of mitochondria by live-cell microscopy - Mitochondria in living cells are 
generally visualized using chemical and/or proteinaceous fluorescent reporter molecules 
("probes"; Fig. 1; [214, 215]). Chemical probes can be introduced into the cells using specific 
incubation protocols whereas protein-based probes require cell transduction or transfection. 
Alternatively, (inducible) cell lines can be created that stably express the protein-based probe 
of interest (e.g. [21, 216-218]). For chemical probes mitochondrial targeting often depends on 
the fact that mitochondria possess a high inside-negative membrane potential (). This 
means that (positively charged) lipophilic cations accumulate in the mitochondrial matrix in a 
-dependent manner according to the Nernst-equation [219]. Often used cations include 
rhodamine-123 (R123), tetramethylrhodamine methyl ester (TMRM), tetramethylrhodamine 
ethyl ester (TMRE) and 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolyl-carbocyanine 
(JC-1). When accompanied by proper control experiments (see [219, 220] and the references 
therein), the mitochondrial fluorescence signal of the above cations constitutes a measure of 
. At sufficiently negative , JC-1 monomers (green fluorescence) accumulate in the 
mitochonrial matrix to such extend that J-aggregates are formed (red fluorescence), allowing 
ratio-metric analasis of . Several non-cationic chemical probes (e.g. members of the 
"mitotracker" family) react with mitochondrial constituents, thereby trapping them in the 
matrix and rendering their mitochondrial localization less  dependent. Protein-based 
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mitochondria-targeted probes generally consist of a mitochondrial targeting-sequence that is 
N-terminally fused to a (spectral variant of the) green fluorescent protein (mitoGFP). Using 
routine equipment, wide-field fluorescence microscopy allows acquisition of two-dimensional 
(2D) images of cells whereas confocal microscopy enables acquisition of three-dimensional 
(3D) image data-sets (z-stacks). In principle, both types of microscopy allow time-lapse 
studies although 3D image acquisition should be fast enough to prevent mitochondrial 
movement artifacts within individual z-stacks. The latter problem is minimized by measuring 
at 20oC (instead of 37oC) thereby reducing mitochondrial motility. Alternatively, a spinning-
disk confocal microscope can be used, which allows more rapid 3D data acquisition. Live-cell 
microscopy in combination with mitochondria-selective probes can be employed for high-
content strategies to simultaneously assess multiple mitochondrial functional properties (e.g. 
), motility, morphology, mass and position [5, 160, 221-223]. However, visual inspection 
and/or manually categorizing of these images will not permit unbiased and quantitative 
analysis of mitochondrial parameters.  
 
Quantification of mitochondrial morphology and content using image analysis - With 
respect to mitochondrial content, the fractional cellular volume occupied by mitochondria has 
been measured based on fluorescence detection of mitoGFP and calcein blue in the cytosol 
[224]. Alternatively, we and others have developed procedures allowing systematic analysis 
of mitochondrial shape, number and mass using fluorescence microscopy images (Table 2). 
This can be carried out using for example the freely available Fiji (http://pacific.mpi-
cbg.de/wiki/index.php/Main_Page) or OpenCV software (www.opencvb.org) or commercial 
programs like Matlab (www.mathworks.com) or Image Pro Plus (www.mediacy.com). 
Automated methods generally apply an image processing algorithm (“pipeline”; Fig. 3A), 
which involves highlighting the position of mitochondrial structures by generation of a binary 
(BIN) image (segmentation), followed by masking of the background-corrected original 
image (COR) using this BIN image. From the BIN image (representing white mitochondrial 
objects on a black background) various mitochondrial parameters (“descriptors”) can be 
extracted. These descriptors include the number of mitochondria per cell (Nc), the mean area 
of individual mitochondria (Am), the mitochondrial mass (which can be approximated in cells 
with a relatively flat morphology by the product of Nc and Am; [219, 222] or by summing up 
all values of Am within a given cell), mitochondrial aspect ratio (AR, a measure of 
mitochondrial length) and mitochondrial formfactor (F, a combined measure of mitochondrial 
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length and degree of branching; [37, 149]). In principle, when combined with an automated 
high-throughput microscopy system the above pipeline allows for automated high-content, 
high-throughput, screening [4, 5, 254]. To illustrate our quantitative approach we segmented 
the mitochondria for various images depicted in figure 1. Visual inspection of the resulting 
BIN images (Fig. 3B) reveals that the above processing pipeline, originally developed for 
R123-stained primary human skin fibroblasts [37, 222], gave correct results for 7 out of 10 
conditions (Fig. 3C, green bars). However, mitochondrial segmentation was not successful in 
panels Bh, Bn and Br, thereby yielding erroneous values for Nc, Am, mitochondrial mass, AR 
and F (Fig. 3C, red bars). This means that prior to implementation of automated processing 
and quantification, a pipeline should be manually validated for the given cell type by visual 
inspection. Once the experimental conditions for successful automated quantification have 
been established for a certain cell type, images yielding erroneous descriptor values can be 
automatically identified and discarded from the analysis by comparing their descriptor values 
with the cell population average. The above results clearly demonstrate that a certain 
experimental strategy (e.g. cell type, mitochondrial probe, microscopy hardware, image 
acquisition procedure) requires a tailor-made processing/analysis pipeline (and vice versa). 
Crucially, it is important to realize that image magnification/resolution (i.e. the used 
microscopy objective) and signal-to-noise (S/N) ratio need to be compatible with the size of 
the (small) mitochondrial objects and the to-be designed processing protocol [37, 162, 222]. 
As an example of quantification of mitochondrial content (i.e. mass) in 2D microscopy 
images, we have previously developed a high-content strategy for primary human skin 
fibroblasts [220, 222]. Mitochondrial mass in these cells can be approximated by multiplying 
the number of mitochondria per cell (Nc) by the mean mitochondrial area (Am) of the 
mitochondrial objects. This strategy is particularly applicable to fibroblasts and other cell 
types with a flat morphology since in this case the lateral cell dimensions (area) greatly 
exceed its axial dimensions (height). Under these conditions the total mitochondrial volume 
can be approximated by the total mitochondrial area (i.e. the product of Nc and Am). To 
demonstrate the application of this approach we investigated the effect of changes in cellular 
metabolic state on mitochondrial shape and mass. Therefore healthy primary skin fibroblasts 
were cultured for 24 h in normal glucose-containing medium (GLU) and medium in which the 
glucose was replaced by galactose (GAL) and dialyzed serum was used (Fig. 4). In cancer 
cells, this maneuver shifts energy metabolism from glycolysis towards OXPHOS-mediated 
ATP generation [255]. Visual comparison of typical live-cell microscopy images suggests that 
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GAL treatment induces mitochondrial fragmentation (Fig. 4A vs. Fig.4B). Image 
segmentation based upon Am [219] followed by visual inspection suggests that mitochondria 
become smaller in GAL-treated cells (Fig. 4C). A more complete analysis for a population of 
cells revealed that GAL treatment does not affect Nc, but significantly reduces Am, 
mitochondrial mass, AR and F. These results suggest that 24 h GAL treatment does not induce 
mitochondrial fragmentation (i.e. Nc is not affected) but leads to mitochondrial shrinkage and 
a reduced mitochondrial mass. However, since we used a -dependent R123 staining for 
mitochondrial visualization, we cannot rule out that GAL treatment induces  depolarization 
to such extent that mitochondria are “missed” in the analysis. Importantly, the reliability of 
using the product of Am and Nc as a measure of mitochondrial mass also depends on cell size. 
This is caused by the fact that larger cells generally contain more and larger mitochondrial 
objects. For instance, in the case of primary skin fibroblasts from patients with isolated CI 
deficiency we analyzed 2D images of cells stained with CM-DCF (chloromethyl-2’,7’-
dichlorofluorescein; see [256] for protocol). This ROS probe is localized in the cytosol and 
revealed that control cells have a size of 100±15% (N=27 cells; CT5120 cell line) whereas a 
size of 183±15% (N=19) was found in a patient cell line (P5171). Similarly, mitochondrial 
mass in P5171 cells was 194% of that in CT5120 cells (Fig. 5A, Fig. 5B), demonstrating that 
mitochondrial mass measurements should be accompanied by cellular size quantification. If 
fluorescent cations are used for mitochondrial staining, some fluorescence signal might be 
originating from the cytosol leading to a distinct peak in the intensity histogram (Fig. 5C). In 
this case, image processing can be used to segment the cytosolic compartment using 
thresholding (T) and median filtering (MED; Fig. 5D). Superposition of the mitochondrial 
BIN image (Fig. 5B) and cytosolic MED image using a Boolean “AND” operation (similar to 
Fig. 3A), can then be used to calculate the mitochondrial mass corrected for cellular size (i.e. 
the ratio between the total mitochondrial area from the BIN image and the total cytosolic area 
from the MED image). The result of this procedure (Fig. 5D; “BIN AND MED” image) 
depicts mitochondria (light blue) within the cytosol (dark blue). 
  
Interpretation of quantitative data for mitochondrial morphology and content in 2D 
microscopy images – In case of primary skin fibroblasts from patients with isolated CI 
deficiency, we observed that individual mitochondria appeared fragmented and/or less 
branched in patient fibroblasts with a severely reduced CI amount and activity (class I), 
whereas patient cells in which these latter parameters were only moderately reduced displayed 
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a normal mitochondrial morphology (class II; [150]). Comparing these mitochondrial 
morphology alterations with other cellular and mitochondrial readouts revealed that, relative 
to class II patients, class I patients displayed an earlier age of disease onset and death, a larger 
reduction in CI enzymatic activity, a greater increase in NADH/ROS levels and lower cellular 
levels of OXPHOS proteins [257]. With respect to ROS signaling, we provided evidence that 
mitochondrial morphology and function are controlled by endogenous ROS and redox 
signaling [38, 228]. A recent conceptual model [20, 148] proposes that mitochondria can exist 
in three morphological “states” of net morphology: (i) a filamentous or “hyperfused” state, (ii) 
an intermediate or “normal” state, and (iii) a fragmented state (Fig. 6A). These morphologies 
have been linked to distinct cellular and mitochondrial metabolic states and conditions, 
supporting the model that mitochondrial function determines mitochondrial morphology and 
vice versa [20, 148, 258-260]. Each of the three morphological states was associated with a 
distinct phenotype of mitochondrial parameters in primary human skin fibroblasts (Fig. 6B). 
Combining this multivariate dataset with its associated “biological” meaning (Fig. 6C) 
allowed correct classification of the observed phenotypes. Of note, using multiple 
mitochondrial parameters allows not only for identification of “classical” filamentous and 
fragmented morphologies but also is able to identify mitochondrial elongation, shrinkage, 
biogenesis and increased fusion/fission (Fig. 6C). 
 
3D analysis of mitochondrial morphology and content - Automated quantification of 
mitochondrial morphology and content has been most successful using wide-field or confocal 
2D images (Table 2). For reasons explained above this strategy is less applicable to thicker 
specimens [222]. However, a “semi-3D” image can be created by collapsing multiple image-
sections from a wide-field or confocal z-stack into a single 2D projection [224, 261]. A more 
advanced strategy consists of calculating a 3D representation of the mitochondrial 
compartment from the z-stack and performing a 3D analysis of mitochondrial number, 
morphology (e.g. sphericity) and content (e.g. total volume). Although the technical 
requirements for image acquisition, processing and analysis are significantly more demanding 
than for 2D procedures, recent attempts to analyze mitochondria in 3D have demonstrated that 
this strategy has promising potential [247]. The latter study as well as others (e.g. [249]) 
demonstrated that additional mitochondrial subtyping (i.e. using more than the three 
categories described above) may also be applied to account for differences in shape and 
appearance. Thus, the descriptors to be analyzed should depend on the physiological or 
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experimental context in the particular study, and whether it is the mitochondrial fragmentation 
state or other shape changes that are of interest. 
 
4. SUMMARY AND CONCLUSIONS 
Until recently, changes in mitochondrial content were explained primarily in terms of 
mitochondrial biogenesis or proliferation, without accounting for removal of damaged 
organelles. However, the cellular mitochondrial content under a given condition results from 
the balance between mitochondrial biogenesis, dynamics and degradation. Since mitochondria 
represent primary sites of both metabolism and cell signaling, they serve as sensors, effectors, 
and executors in various physiological processes to accommodate contextual influences. This 
includes adaptive responses to re-establish a new steady state situation for the cell, or cell 
death if the effects are severe and vital physiological thresholds are crossed. The 
mitochondrial responses are thus manifold, and serve to balance metabolic and energetic 
needs in the cell. Therefore studies of mitochondrial content cannot be completely dissociated 
from the physiological cellular context that (co)determines an observed mitochondrial content 
change. This means that interpretation of the obtained data needs to consider at least two 
major questions in order to evaluate the potential effects on mitochondrial physiology: (i) To 
what extent does the observed results reflect, or relate to, the authentic physiological context 
in a viable cell or tissue? (ii) Is it possible that the observed effect is reciprocally balanced or 
compensated by other mechanisms in the cell (adaptation)? Although, “mitochondrial 
number” still might represent a useful descriptor for some applications and tissues, it does not 
properly reflect the content of mitochondrial biomass since it depends on the specificities of 
mitochondrial morphology and size, and phenomena such as fusion and fission. Therefore 
computer-assisted 2D and 3D analysis of live-cell microscopy images provides a promising 
strategy for quantification and statistical analysis of mitochondrial shape and content in an 
unbiased manner. However, experimental conditions and the used cell type should be 
compatible with the applied quantification approach and not be applied without a proper 
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, mitochondrial membrane potential 
AICAR, 5-aminoimidazole-4-carboxamide riboside 
Am, the area of individual mitochondris 
AMPK, AMP-dependent protein kinase 
AR, mitochondrial aspect ratio 
BIN, binary image 
BNIP3, Bcl2/adenovirus E1B 19-kDa protein-interacting protein 3 
CM-DCF, chloromethyl-2’,7’-dichlorofluorescein 
COR, background-corrected microscopy image 
Drp1, dynamin-related protein 1 
EM, electron microscopy 
ERRα, estrogen-related receptor alpha 
ETC, electron transport chain 
F, mitochondrial formfactor 
Fis1, fission protein 1 
GFP, green fluorescent protein 
JC-1, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolyl-carbocyanine 
MIM, mitochondrial inner membrane 
MED, median (filtered) image 
MEF2, myocyte enhancer factor 2 
Mfn1/2, mitofusin 1/2 
MOM, mitochondrial outer membrane 
mtDNA, mitochondrial DNA 
Nc, number of mitochondria per cell 
nDNA, nuclear DNA 
NRF-1, nuclear respiratory factor-1 
NRF-2, nuclear respiratory factor-2 
OPA1, optic atrophy protein 1 
OXPHOS, oxidative phosphorylation 
PARIS, parkin interacting substrate 
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PARL, presenilin-associated rhomboid-like 
PGC-1α, peroxisome proliferator-activated receptor gamma coactivator-1α 
PINK1, PTEN (phosphatase and tensin homolog)-induced putative kinase 
POLRMT, mitochondrial RNA polymerase 
PPAR, peroxisome proliferator-activated receptor 
R123, rhodamine 123 
ROS, reactive oxygen species 
RXR, retinoid X receptor 
SIM, structured-illumination microscopy 
S/N, signal-to-noise 
T, thresholding, thresholded 
TCA, tricarboxylic acid cycle 
TFAM, Transcription factor A, mitochondrial 
TFB, transcription factor B 
TMRE, tetramethylrhodamine ethyl ester 
TMRM, tetramethylrhodamine methyl ester 
UCP-1, uncoupling protein-1  
VCP, valosin-containing protein  






Figure 1: Mitochondrial morphology in various cell types. Mitochondria were visualized 
by live-cell microscopy in the indicated cell types using either a chemical (i.e. JC1, MR, 
R123, TMRM) or a protein-based reporter molecule (mitoEYFP). The scale bar equals 15 µm. 
(A) Primary human myoblast (HM) stained with rhodamine 123 (R123). (B) Primary mouse 
myoblast (MM) stained with Mitotracker Red CMXRos (MR). (C) Primary human skin 
fibroblast (HSF) stained with tetramethylrhodamine ethyl ester (TMRM). (D) Primary mouse 
skin fibroblast (MSF) stained with R123. (E) Primary mouse hippocampal glia cell (MHG) 
stained with R123. (F) Primary mouse hippocampal neuron (MHN) stained with R123. (G) 
Primary rat pancreatic acinar cells (RPAC) stained with R123. (H) Primary human myotubes 
(HMT) stained with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolyl- carbocyanine (JC-
1). (I) Buffalo Green Monkey kidney (BGM) cells expressing mitochondria-targeted 
enhanced yellow fluorescent protein (mitoEYFP). (J) Primary human skin fibroblast (HSF) 
expressing mitoEYFP. (K) Primary human myotubes (HMT) expressing mitoEYFP. (L) 
Chinese Hamster Ovary (CHO) cells expressing mitoEYFP.  
 
Figure 2: Regulation of mitochondrial biogenesis, dynamics and degradation in 
mammalian cells. Mitochondrial content depends on the cell-controlled balance between 
mitochondrial biogenesis (activated by endogenous or exogenous signals), mitochondrial 
degradation and mitochondrial dynamics. The latter is controlled by a variety of regulatory 
signals (see Section 2 in the main text for details).  
 
Figure 3: Quantification of mitochondrial morphology in selected cell types. (A) Image 
processing and analysis flow scheme for quantification of mitochondrial morphology 
parameters in living cells. A fluorescent reporter molecule is used to specifically visualize 
mitochondria and a microscopy image is taken. This image (RAW) is background-corrected 
(BC) to yield the COR image. The latter image is subsequently processed by a linear contrast 
stretch (LCS) operation, a top-hat filter (THF), a median filter (MED) and thresholded (T) to 
yield a binary (BIN) image. The BIN image highlights white mitochondrial objects on a black 
background. Combination of the BIN and COR image using a Boolean “AND” operation 
allows calculation of a masked image (MSK) and calculation of fluorescence intensity 
information for each mitochondrial object. (B) Calculation of the BIN image for a variety of 
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cell types (live-cell images were taken from figure 1) by applying the algorithm in panel A. 
(C) Parameters extracted from the BIN images: calculation of the number of mitochondrial 
objects per cell (Nc), the mean area of each individual mitochondrial object (Am), 
mitochondrial mass (calculated by taking the product of Nc and Am, the mean mitochondrial 
object aspect ratio (AR, a measure of mitochondrial length) and the mean mitochondrial object 
formfactor (F, a combined measure of mitochondrial length and degree of branching). In this 
panel, the designation of the corresponding binary image in panel B is given on the x-axis. 
Not all binary images in panel B yielded correct results. Reliable data are represented by 
green columns; incorrect data is represented by red columns. Data obtained using a different 
magnification is indicated by #. Error bars represent standard error of the mean (SEM).     
 
Figure 4: Mitochondrial shrinkage and content reduction visually resemble 
mitochondrial fragmentation. Mitochondrial morphology was analyzed in R123-stained 
primary human skin fibroblasts from a healthy volunteer (CT5120). These cells were cultured 
in normal medium containing 5.5 mM glucose (GLU) and in the same medium without GLU 
but with 5.5 mM galactose (GAL) and dialyzed serum for 24 h. (A) Typical COR and BIN 
image (see figure 2 and main text for details about the image processing) of cells cultured in 
GLU-containing medium. (B) Similar as panel A but now for cells cultured in GAL-
containing medium. (C) Segmentation of differently-sized mitochondria for the GLU (panel 
A) and GAL (panel B) condition based upon their area (Am) from large (>1000) to small (10-
20). (D) Average values of Nc, Am, mitochondrial mass, AR and F (see figure 2 and main text 
for the meaning of these parameters) for GLU and GAL conditions in a number (N) of cells. 
 
Figure 5: Mitochondrial mass and relevance of cell size. (A) Typical RAW and BIN image 
(see figure 2 for details about the image processing) of TMRM-stained primary human skin 
fibroblasts from a healthy volunteer (CT5120). The integrated optical density in the BIN 
image divided by 2, which is proportional to the total number of mitochondrial pixels in a 
single cell, equaled 2094190. (B) Similar to panel A but now for fibroblast from a patient with 
mitochondrial disease due to an isolated mitochondrial complex I deficiency (P5171; [262]. 
Here the integrated optical density in the cell equaled 4056290 (i.e. 194% of CT5120 cells). 
(C) Intensity histogram and magnification (inset) of the RAW image in panel B. Using a 
threshold value of 16 (gray value) allows segmentation of the cytosolic compartment (see also 
panel D). (D) Calculation of the cytosolic area using the RAW image in panel B. Following a 
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threshold operation (T), the image is median-filtered (MED; 3x3 filter size, 3 times) and 
combined with the BIN image in panel B using a Boolean “AND” operation (BIN AND 
MED). The latter figure depicts mitochondria (light blue) within the cytosol (dark blue). The 
total number of mitochondrial pixels equaled 4056290 (i.e. 9.54% of the total number of 
cytosolic pixels equaling 42513000).  
 
Figure 6: Functional consequences and quantification of mitochondrial morphology and 
mass alterations. (A) Binary (BIN) images obtained by image processing of microscopy 
images from primary human skin fibroblasts stained with R123. Cells were obtained from a 
healthy volunteer (CT5120; “filamentous” and “intermediate” panel) and a patient with 
isolated mitochondrial complex I deficiency (P6173: “Fragmented” panel). Mitochondrial and 
cellular conditions/properties associated with the filamentous and fragmented phenotypes are 
indicated. (B) Quantitative parameters extracted from the BIN images in panel A. Depicted 
are the number of mitochondrial objects per cell (Nc), the mean area of each individual 
mitochondrial object (Am), mitochondrial mass (calculated by taking the product of Nc and 
Am, the mean mitochondrial object aspect ratio (AR, a measure of mitochondrial length) and 
the mean mitochondrial object formfactor (F, a combined measure of mitochondrial length 
and degree of branching). Data was expressed as percentage of the average value obtained for 
cells with an intermediate mitochondrial morphology phenotype. (C) Classification scheme of 
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Table.1: Selected examples of pharmacological modulation of mitochondrial morphology and mass in mammalian cells 
Species Tissue/Cell type Treatment/condition Mechanism Methods and measurements Mitochondrial effects Refs 
       
Human Cancer and non-
cancer cell lines, 
HUVECs 
AICAR AMPK, AKT Biochemical biomarkers, 
Microscopy 
Increased content and functionality 
Cell-type dependent effects 
[25, 32] 









Increased content and functionality [26] 
Human CEM cells d4T, ddC, ddI Cell 
stress/death 











Increased content and functionality [28] 
Human MRC-5 H2O2 ROS mtDNA, flow cytometry Increased content [29] 




Increased content [30] 
Rat Enriched cortical 
neurons /Primary 
neuronal cultures 







Increased content and functionality [31] 





Increased content [32] 
Mice Skeletal Muscle 
C2C12 cells 




Reduced content and functionality [33]  









Increased content and functionality [34, 35] 






Increased content and functionality [36]  
Human Primary skin 
fibroblasts 





Increased length and degree of 
branching 
[37] 
Human Primary skin 
fibroblasts 




Increased length and degree of 
branching and functionality 
[38] 





Increased content and functionality [39-41] 
Abbreviations: AICAR, 5-aminoimidazole-4-carboxamide riboside, AKT, v-akt murine thymoma viral oncogene homolog, AMPK, AMP-dependent protein kinase, d4T, 
2',3'-didehydro-3'-deoxythymidine, ddC, 2',3'-dideoxycytidine, ddI, 2',3'-dideoxyinosine, DETA-NO, (Z)-1-[2-(2-aminoethyl) -N-(2-ammonioethyl) amino]diazen-1-ium-1,2 
diolate, eNOS, endothelial nitric oxide synthase, HUVECs, human umbilical vein endothelial cells, LPS, lipopolysaccharide, MEFs, mouse embryonic fibroblasts, Mfn2, 
mitofusin 2, mtDNA, mitochondrial DNA, mTOR, mammalian target of rapamycin, NO, nitric oxide, NRF-1, nuclear respiratory factor-1, PGC-1α, peroxisome 
proliferator-activated receptor gamma coactivator-1α, PPARs, peroxisome proliferator-activated receptors, ROS, reactive oxygen species, SIRT1, silent mating type 
information regulation 2 homolog 1, TFAM, Transcription factor A, mitochondrial, Trolox, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, TTA, 
Tetradecylthioacetic acid.  
Table 2: Selected studies applying quantitative analysis of mitochondrial morphology parameters 
Cell type Mode Staining Microscopy Algo Parameters Refs 
       
PHSF 2D R123-pulse Video-rate CLSM A Am, AR, F, Nc, F/Nc, Mass, width, length [37, 149, 150, 162, 222, 225] 
PHSF 2D TMRM Epifluorescence  A Am, AR, F, Nc, width, length [38, 219, 226-228]  
PHSF 2D MitoGFP Epifluorescence  A Am, AR, F, Nc, width, length [219] 
PHSF 2D MitoEYFP CLSM A F, Nc, F/Nc [229] 
PHSF 2D Anti-GRP75 Epifluorescence A F [230, 231]  
N2a 2D R123-pulse Video-rate CLSM A AR, F, Nc [232] 
PHMyob 2D R123-pulse Video-rate CLSM A AR, F, Nc [233]  
HeLa 2D R123-pulse Video-rate CLSM A F, Nc [38, 218] 
SH-SY5Y 2D MitoDsRed2 CLSM A AR [234] 
SH-SY5Y 2D MitoDsRed2 CLSM A AR [235] 
PMEFs 2D TMRM Epifluorescence  A Am, F, Nc, Mass [236]  
CHO  2D TMRM Epifluorescence  A F, Nc [38] 
IMEFs 2D TMRM Epifluorescence  A F, Nc [38] 
CEA 2D TMRM CLSM A Am, AR, Nc [237] 
CEH 2D TMRM CLSM A Am, AR, Nc [237] 
CEMC 2D MitoGFP CLSM A AR, F [238] 
M17HN 2D MitoDsRed2 CLSM A AR  [239] 
CV1 2D MitoDsRed Epifluorescence B AR [240, 241] 
C9, H9c2 2D RFP Epifluorescence B AR, F [242] 
H9c2 2D Mitotracker Red Epifluorescence B AR, F [243] 
C9, H9c2 2D Various Epifluorescence B AR, F [244]  
MM 2D MitoroGFP2 Epifluorescence B Am, F, P [245]  
U2OS 2D MitoDsRed2 CLSM B Length, Am, Mass, others [246]  
PHSF 3D MitoDsRed2 Epifluorescence + decon. C V, BP, Nc, NPC [247]  
HUVEC 2D Mitotracker Green Epifluorescence D AR, F, length [248]  
CHO 2D MitoDsRed Epifluorescence E Morphology, skeleton, and binary texture features [249]  
PC12 2D MitoDsRed2 Epifluorescence F Am, Nc, length [250] 
SH-SY5Y 2D Mitotracker Red CLSM G TMA [251] 
CEMN 2D MitoDsRed CLSM H Am, Nc [252] 
RCN 2D MitoDsRed2 Epifluorescence I Nc, length [253] 
Quantification algorithms: A = [37, 162, 219, 222]; B = Variant of algorithm A; C = [247]; D = [248]; E = [249]; F = [250]; G = [251]; H = [252]; I = [253] Abbreviations: 
AFM, atomic force microscopy; Algo, mitochondrial morphology quantification algorithm; Am, mitochondrial area (size); AR, aspect ratio; BP, mitochondrial branching points; 
C9, clone 9 rat liver cell; CEA, chicken embryo astrocytes; CEH, chicken embryo hepatocytes; CEMC, C. elegans muscle cells; CEMN, chick embryo motor neurons; CHO, 
Chinese hamster ovary; CLSM, confocal laser scanning microscopy; CV1, monkey kidney fibroblast cells; decon, deconvolution; F, formfactor; F/Nc, mitochondrial 
complexity; GRP75, mitochondrial heatshock protein 70 (mtHSP70); H9c2, cardiac myoblast cell; HUVEC, human umbilical vein endothelial cell; IMEF, immortalized mouse 
embryonic fibroblast; IRHM, isolated rat heart mitochondria; MitoEYFP, mitochondria-targeted enhanced yellow fluorescent protein; MitoGFP, mitochondria-targeted green 
fluorescent protein; MitoroGFP2, mitochondria-targeted redox-sensitive green fluorescent protein 2; M17HN, M17 human neuroblastoma; MM, malignant mesothelioma; n.a., 
not appropriate; N2a, mouse neuroblastoma cell line; Nc, number of mitochondria per cell; NPC, mitochondrial networks per cell; P, mitochondrial perimeter; PC12, rat 
pheochromocytoma cell; PHMyob, primary human myoblasts; R123, rhodamine 123; RCN, rat cortical neurons; PHSF, primary human skin fibroblasts; PMEF, primary mouse 
embryonic fibroblast; RFP, red fluorescent protein; SH-SY5Y, human dopaminergic neuroblastoma clonal cell; TMA, total mitochondrial area; TMRM, tetramethylrhodamine 
methylester; U2OS, human osteosarcoma cell line; V, mitochondrial volume. 
 
 
